•Scipromed was founded in 2023 in CHAMPIONBIO, Beijing, China
•Scipromed's technology system originated from the Chinese Academy of Sciences. It has been supported by the National "863" Program in the field of antibody engineering for 25 consecutive years. It has pioneered the development of anti-tumor bispecific antibodies and trispecific antibodies in both China and abroad. As the core technical team of the global preferred service provider, it has provided antibody discovery technology to large American pharmaceutical companies for six years.
•Scipromed's primary focus is the development of bispecific antibody drugs and ADC drugs for the treatment of tumors. Additionally, the company produces and sells cell culture medium protein products, meeting the demands of the CGT, medical beauty, and large health sectors.
•Sciprotech is a cell culture protein product brand under Scipromed. It sells self-produced and Tonghua Anrate's cell culture medium protein products.
•Tonghua Anrate has granted Scipromed global agency qualifications to represent the marketing and sales of cell culture medium protein products such as recombinant human albumin and recombinant human transferrin.
中文